___
PT-141 · Neurological Desire Support
PT-141 in Ann Arbor
PT-141 (bremelanotide) is FDA-approved as Vyleesi® for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is prescribed only after a clinical consultation. Other uses are off-label and are discussed only during a consultation.

PT-141
Bremelanotide · Brand Name: Vyleesi®
Mechanism: Melanocortin receptor agonist. FDA-approved as Vyleesi® for HSDD in premenopausal women.
PT-141 acts centrally in the brain rather than on blood flow, engaging pathways involved in sexual desire.
Individual response and administration are determined at consultation.
Pricing for PT-141 (Vyleesi®) is discussed at consultation.
Common side effects and contraindications are reviewed individually at consultation.
FDA status disclosure: PT-141 is FDA-approved as Vyleesi® for HSDD in premenopausal women only. Other uses are off-label and are discussed only during a consultation.
How PT-141 Works
PT-141
Activates the neurological pathway associated with sexual desire. Individual response and administration are discussed at consultation.
PT-141 · Ann Arbor
Desire Isn't Just
Vascular. Treat the
Whole System.
PT-141 is assessed at consultation alongside hormone panels and a complete clinical history, guided by a clinician who understands the vascular, hormonal, and neurological dimensions of desire.
PT-141 · Pricing at consultation



.webp)

